Projects funded by the NCN

New amide derivatives of cinnamic acid as a carbonyl reductase inhibitors, which modulate the activity of doxorubicin - ...

Call: SONATA 11 , Panel: NZ7

Principal investigator: dr Paulina Koczurkiewicz-Adamczyk

Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Farmaceutyczny

Modified borondipyrromethane derivatives (BODIPY) with selective photodynamic activity against cancer and bacterial cell...

Call: SONATA 11 , Panel: NZ7

Principal investigator: dr hab. Jarosław Piskorz

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny

Targeting Nrf2-ARE pathway for chemoprevention and /or therapy of the liver and the pancreas cancers by naturally occurr...

Call: OPUS 11 , Panel: NZ5

Principal investigator: dr hab. Violetta Krajka-Kuźniak

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny

Liposomal theranostic agent for magnetic resonance imaging and photodynamic therapy

Call: SONATA 11 , Panel: NZ7

Principal investigator: dr Paulina Skupin-Mrugalska

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny

Chemically modified mRNA for studies on cellular processes and therapeutic applications

Call: OPUS 11 , Panel: ST5

Principal investigator: prof. Jacek Jemielity

Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego

Characterization and improvement of anti-cancer properties of second generation antagonists of Mdm2 oncoprotein

Call: SONATA 11 , Panel: NZ7

Principal investigator: dr Łukasz Skalniak

Uniwersytet Jagielloński, Wydział Chemii

New, multifunctional nanoparticles for combined photothermal and gene silencing cancer therapy

Call: OPUS 11 , Panel: ST8

Principal investigator: prof. Stefan Jurga

Uniwersytet im. Adama Mickiewicza w Poznaniu, Centrum Nanobiomedyczne

Immunomodulatory properties of nanosystems containing membrane-active compounds and their potential in therapy of drug r...

Call: PRELUDIUM 10 , Panel: NZ6

Principal investigator: Ewelina Piktel

Uniwersytet Medyczny w Białymstoku, Wydział Lekarski z Oddziałem Stomatologii i Oddziałem Nauczania w Języku Angielskim

Discovery and development of small-molecule inhibitors of USP2 for targeted, non-genotoxic therapy of cancer

Call: OPUS 1 , Panel: ST5

Principal investigator: prof. Tadeusz Holak

UNIWERSYTET JAGIELLOŃSKI, Wydział Chemii

In vitro and in vivo preclinical studies of NaA nanozeolite functionalized with antibodies anti-PSMA and labeled with ra...

Call: OPUS 10 , Panel: NZ7

Principal investigator: prof. Anna Lankoff

Instytut Chemii i Techniki Jądrowej

Nanoparticle conjugates with the monoclonal antibody - a new opening in target tumor therapy

Call: PRELUDIUM 10 , Panel: NZ3

Principal investigator: Monika Marcinkowska

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Genome abberations, p53 status and nitrosative-oxidative stress manifestation during establishment of methotrexate-induc...

Call: OPUS 1 , Panel: NZ4

Principal investigator: dr hab. Magdalena Dąbrowska

INSTYTUT BIOLOGII DOŚWIADCZALNEJ PAN IM.M.NENCKIEGO

The use of insulin and glucose conjugates for the targeted therapy of breast cancer

Call: PRELUDIUM 10 , Panel: NZ5

Principal investigator: Siddarth Agrawal

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Lekarski

New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

Call: OPUS 9 , Panel: ST5

Principal investigator: prof. Artur Terzyk

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Mechanism of death induced in cancer cells by photodynamic therapy by means of porphycene photosensitizers.

Call: PRELUDIUM 9 , Panel: ST4

Principal investigator: Natalia Masiera

Instytut Chemii Fizycznej PAN

The role of DNA methylation in enhancing the sensitivity of colorectal cancer cells to topoisomerase inhibitors.

Call: PRELUDIUM 9 , Panel: NZ3

Principal investigator: Alicja Pawlak

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN

Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

Call: PRELUDIUM 9 , Panel: NZ5

Principal investigator: Zofia Bielecka

Wojskowy Instytut Medyczny